Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy

• Published in: Journal of anatomy 2023-01, Vol.242 (1), p.29-49
• Main Authors: Malone, Grainne, Abdelsayed, Gerges, Bligh, Fianait, Al Qattan, Fatma, Syed, Saifullah, Varatharajullu, Prateepan, Msellati, Augustin, Mwipatayi, Daniela, Azhar, Maimoona, Malone, Andrew, Fatimi, Saulat H., Conway, Claire, Hameed, Aamir
• Format: Article
• Language: English
• Subjects: Blood clots; blood coagulopathy; Blood flow; Blood vessels; Clinical trials; Coagulants; Congestive heart failure; Heart failure; Heart Failure - therapy; Heart-Assist Devices - adverse effects; Humans; Ischemia; left ventricular assist devices; mechanical circulatory support; pump thrombosis; Thrombosis; Thrombosis - etiology; Thrombosis - prevention & control; thrombus; Ventricle
• ISSN: 0021-8782; 1469-7580
• DOI: 10.1111/joa.13675

Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are very useful in improving outcomes in patients with advanced‐stage heart failure. Despite recent advances in LVAD development, pump thrombosis is one of the most severe adverse events caused by LVADs. The contact of blood with artificial materials of LVAD pumps and cannulas triggers the coagulation cascade. Heat spots, for example, produced by mechanical bearings are often subjected to thrombus build‐up when low‐flow situations impair washout and thus the necessary cooling does not happen. The formation of thrombus in an LVAD may compromise its function, causing a drop in flow and pumping power leading to failure of the LVAD, if left unattended. If a clot becomes dislodged and circulates in the bloodstream, it may disturb the flow or occlude the blood vessels in vital organs and cause internal damage that could be fatal, for example, ischemic stroke. That is why patients with LVADs are on anti‐coagulant medication. However, the anti‐coagulants can cause a set of issues for the patient—an example of gastrointestinal (GI) bleeding is given in illustration. On account of this, these devices are only used as a last resort in clinical practice. It is, therefore, necessary to develop devices with better mechanics of blood flow, performance and hemocompatibility. This paper discusses the development of LVADs through landmark clinical trials in detail and describes the evolution of device design to reduce the risk of pump thrombosis and achieve better hemocompatibility. Whilst driveline infection, right heart failure and arrhythmias have been recognised as LVAD‐related complications, this paper focuses on complications related to pump thrombosis, especially blood coagulopathy in detail and potential strategies to mitigate this complication. Furthermore, it also discusses the LVAD implantation techniques and their anatomical challenges. Left ventricular assist device (LVAD)‐related blood coagulopathy: Pump thrombosis is one of the most severe adverse events caused by LVADs. The contact of blood with artificial materials of LVAD pumps and cannulas triggers the coagulation cascade.